BCL2 and lymphoma: While the BCL2 inhibitor venetoclax has shown modest single‐agent activity in aggressive lymphomas, including diffuse large B‐cell lymphoma (DLBCL) and peripheral T‐cell lymphoma (PTCL), durable remissions are rarely observed.7, 8